BioLamina secures €20M to scale cell therapy tech
EIB backs Swedish biotech scale-up BioLamina with €20 million to enable stem cell technologies targeting diseases such as type 1 diabetes, Parkinson’s disease, and heart failure
BioLamina has secured €20 million in financing from the European Investment Bank. The investment will support the scale-up of technologies used in cell therapy and broader ATMP development. This funding is backed by the InvestEU programme. As a result, BioLamina can expand production capacity and improve its manufacturing processes.
Enabling next-generation ATMPs
BioLamina develops laminin-based substrates that support the growth of high-quality cells. These materials are essential for reliable and scalable cell & gene therapy development. Importantly, the company’s technologies are already used by researchers and industry worldwide. They help address a key challenge in ATMPs – consistent and reproducible cell production.
Supporting innovation in cell and gene therapy
The funding will strengthen BioLamina’s product portfolio and technological base. At the same time, it will support Europe’s ambition to lead in cell therapy and regenerative medicine. Cell-based treatments developed using these technologies target serious diseases. These include type 1 diabetes, Parkinson’s disease, heart failure, and cancer.
Strengthening Europe’s ATMP ecosystem
The financing is structured as venture debt. Therefore, BioLamina can scale without immediate shareholder dilution. Overall, the investment highlights how European institutions support innovation in ATMPs. It also reinforces efforts to translate scientific breakthroughs into scalable healthcare solutions.
